Windward Bio
Business Services · Switzerland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Aeschenplatz 6, Basel, Basel-City, 4052,...Website
www.windwardbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Windward Bio
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.Explore more
Windward Bio Org Chart
SA
Chief Legal & Business Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Windward Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Windward Bio recently announced quarterly report
Check out if Windward Bio is spiking on competitors!
Click to see if Windward Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Windward Bio launches new products
Check if Windward Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Windward Bio
Funding: Get notified immidiatlly once Windward Bio has new funding data
Windward Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Windward Bio
Find 2 more new buyers
Company Profile Activity
Activity Insights
Windward Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Windward Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Windward Bio.
Windward Bio financials insights
Gather financial insights about Windward Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$200M
2026
Other Financing Round
$165M
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Partnership
Partnership, Research & Development, Product Management, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Windward Bio News & Media
Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378
BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced that the first patients have been dosed in the Phase 2 SIRIUS study of WIN378, the company’s ultra long-acting anti-TSLP monoclonal antibody, in patients with chronic obstructive pulmonary disease (COPD).Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
BASEL, Switzerland, May 04, 2026 (GLOBE NEWSWIRE) -- Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165M crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The finHarbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today...Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
BASEL, Switzerland, Dec. 21, 2025 (GLOBE NEWSWIRE) -- Windward Bio AG, a private, clinical-stage biotechnology company committed to improving the lives of people living with advanced immunological diseases, today announced a licensing agreement between its affiliate, LE2025 Therapeutics AG, and Qyuns Therapeutics for the development and commercialization of WIN027 (also known as QX027N), a potential best-in-disease, long-acting bispecific antibody targeting TSLP and IL-13.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Windward Bio
Sign Up For FreeTo access detailed company insights
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. T... Read More
